2026-2032 年食品疫苗市场（按类型、应用和地区）

食品疫苗市场评估-2026-2032

替代疫苗接种方法的需求日益增长，尤其是在发展中地区，这推动了人们对可食用疫苗的兴趣。感染疾病的日益普及以及人们对预防医学日益增长的兴趣，正在推动该领域的研究投资和创新。 2023年，可食用疫苗的需求将超过83.5亿美元，到2032年将达到129.1亿美元。

此外，植物生物技术的进步使得透过基因改造作物生产疫苗成为可能，也使得食用疫苗的生产更加可行。食用疫苗的成本效益、易储存和易于运输特性进一步推动了市场扩张，因为它们解决了全球疫苗接种工作中的一个关键挑战。这些因素正在推动各行各业对食用疫苗的使用日益增多，预计2026年至2032年的复合年增长率将达到6.18%。

食品疫苗市场定义/概述

食品疫苗是指基因改造作物或植物，其产生的抗原在摄取后会刺激免疫反应，从而提供一种简单、无需针头的疫苗接种方法。其主要应用包括控制B肝、霍乱和狂犬病等感染疾病，而传统的疫苗接种方式在后勤和取得方面存在障碍。未来，食品疫苗有望成为一种广泛且经济有效的疫苗接种方式，尤其是在资源匮乏的地区，因为它们可以减少对低温运输的依赖并降低生产成本。植物生物技术的发展和人们对预防医学日益增长的兴趣预计将推动未来的发展，使食品疫苗成为全球公共卫生倡议中一个极具潜力的工具。

预防保健意识的不断增强会推动食品疫苗市场的发展吗？

预防保健意识的提升是食品疫苗市场的主要驱动力。随着人们预防性卫生意识的增强，人们开始采取积极主动的措施来对抗疾病，这导致人们对食品疫苗等创新疫苗解决方案的兴趣日益浓厚。世界卫生组织 (WHO) 指出，每年约有 150 万人死于疫苗可预防的疾病，凸显了製定有效疫苗接种策略的必要性。美国疾病管制与预防中心 (CDC) 报告称，随着疫苗接种意识的不断提高，儿童脊髓灰质炎和麻疹等疾病的疫苗接种率已接近 95%。

这种对可及性和非侵入性疫苗解决方案的需求，尤其是在医疗基础设施有限的地区，与可食用疫苗的优势相得益彰，进一步刺激了市场发展。此外，可食用疫苗为疫苗接种中的一个关键物流挑战提供了解决方案。与传统疫苗不同，它们无需冷藏，尤其适用于缺乏稳定低温运输基础设施的地区。根据联合国的报告，超过30%的低收入国家面临低温运输短缺，影响了有效免疫接种的发展。食品疫苗可以帮助应对这些挑战，因为它们可以在当地以更少的资源生产和分销。

高成本和高可近性会阻碍食品疫苗市场的成长吗？

高成本和供应不足可能会阻碍可食用疫苗市场的成长。可食用疫苗的开发需要先进的基因工程、严格的临床试验和监管部门的核准，所有这些都会增加生产成本。这些费用可能会限制人们的可负担性，尤其是在中低收入国家，因为这些国家的传统疫苗通常由政府计画和国际组织津贴。如此高成本结构可能会减缓疫苗的普及速度，尤其是在资源有限的地区。

此外，由于并非所有地方都具备大规模种植和推广基改作物的基础设施，食品的可及性仍然是一个问题。在欧洲等地区，严格的作物改造法律规范也构成了障碍，可能会限制食品疫苗的推广。因此，儘管食品疫苗具有良好的前景，但其高昂的成本和有限的供应对其广泛应用构成了重大挑战。

目录

第一章：全球食品疫苗市场简介

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章 食品疫苗的全球市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

第五章全球食品疫苗市场（按应用）

• 概述
• 家畜
• 医疗保健

6. 全球食品疫苗市场（按类型）

• 概述
• 灭活疫苗
• 其他的

7. 全球食品疫苗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第八章全球食品疫苗市场竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第九章 公司简介

• GlaxoSmithKline
• Sanofi SA
• Merck & Co., Inc.
• Ceva
• Santa Cruz Animal Health
• Merial

第十章 重大进展

• 产品发布/开发
• 合併与收购
• 业务扩展
• 伙伴关係与合作

第十一章 附录

• 相关调查

Edible Vaccine Market Valuation - 2026-2032

The rising demand for alternative vaccination methods, particularly in developing regions, is propelling interest in edible vaccines as they offer an easier, needle-free delivery mechanism that enhances accessibility and compliance. Increasing prevalence of infectious diseases and growing focus on preventive healthcare are encouraging research investments and innovation in this field. The need for edible vaccine is surpassing USD 8.35 Billion in 2023 and reaching USD 12.91 Billion by 2032.

Additionally, advances in plant biotechnology, which enable the genetic modification of crops to produce vaccines, have strengthened the feasibility of edible vaccines. The cost-effectiveness, ease of storage, and transport of edible vaccines further fuel market expansion as these factors address critical challenges in global immunization efforts. These factors contribute to the increasing use of edible vaccine in a variety of industries is expected to grow at a CAGR of 6.18% about from 2026 to 2032.

Edible Vaccine Market: Definition/ Overview

Edible vaccines are genetically engineered crops or plants that produce antigens, stimulating an immune response when consumed, offering a needle-free, easily administered vaccination method. Their primary applications include combating infectious diseases like hepatitis B, cholera, and rabies, where traditional vaccination faces logistical or accessibility barriers. Looking ahead, edible vaccines hold potential for widespread, cost-effective immunization, especially in low-resource settings, as they reduce cold-chain dependency and production costs. Advances in plant biotechnology and growing interest in preventive health are expected to drive future developments, making edible vaccines a promising tool for global public health initiatives.

Will Growing Awareness of Preventive Healthcare is Propelling the Edible Vaccine Market?

Growing awareness of preventive healthcare is significantly propelling the Edible Vaccine Market. As populations become increasingly conscious of preventive health, there is a shift towards proactive measures in combating diseases, boosting interest in innovative vaccination solutions like edible vaccines. The World Health Organization (WHO) notes that vaccine-preventable diseases cause approximately 1.5 million deaths each year, emphasizing the need for effective immunization strategies. In the United States, the Centers for Disease Control and Prevention (CDC) reports a rising trend in vaccination awareness, with vaccination coverage among children reaching nearly 95% for diseases like polio and measles, showcasing the population's inclination toward preventive healthcare.

This demand for accessible, non-invasive vaccine solutions, particularly in regions with limited healthcare infrastructure, aligns with the benefits of edible vaccines, further fueling the market. Additionally, edible vaccines offer solutions to critical logistical challenges in vaccination. Unlike traditional vaccines, they don't require refrigeration, making them especially suitable for areas without consistent cold-chain infrastructure. According to a United Nations report, over 30% of low-income countries face cold chain shortages, which impact effective immunization coverage. Edible vaccines can help address these challenges, as they can be produced and distributed locally with fewer resources.

Will High Costs and Accessibility Hamper the Growth of the Edible Vaccine Market?

High costs and accessibility challenges could hamper the growth of the Edible Vaccine Market. Developing edible vaccines requires advanced genetic engineering, rigorous clinical trials, and regulatory approvals, all of which add to production costs. These expenses may limit affordability, especially in low- and middle-income countries where traditional vaccines are often subsidized by government programs or international organizations. This high-cost structure could slow adoption rates, particularly in regions where funding is limited.

Moreover, accessibility remains a concern as infrastructure for large-scale cultivation and distribution of genetically engineered crops may not be available everywhere. Strict regulatory frameworks governing genetically modified organisms (GMOs) in regions like Europe also present obstacles, potentially restricting edible vaccine deployment. As a result, while edible vaccines offer promising benefits, high costs and accessibility limitations pose significant challenges to their widespread adoption.

Category-Wise Acumens

Will Widespread Usage for Inactivated Vaccine Boost the Edible Vaccine Market?

The widespread usage of inactivated vaccines can indirectly boost the Edible Vaccine Market. Inactivated vaccines are well-regarded for their safety and effectiveness, fostering trust in vaccine-based preventive healthcare. This acceptance creates a favorable environment for innovative vaccines like edible vaccines, as the public becomes more open to varied vaccination methods. As awareness of different vaccine types grows, so does the interest in more accessible, needle-free alternatives, which could drive adoption of edible vaccines, especially in communities with high demand for convenient immunization options.

Furthermore, as inactivated vaccines require careful storage and distribution, edible vaccines offer an appealing alternative in areas where cold-chain logistics are challenging. Since edible vaccines can be produced in plants, they eliminate the need for cold storage and complex distribution, addressing critical barriers associated with inactivated vaccines in low-resource settings. This added advantage could position edible vaccines as a complementary solution, further enhancing the market's growth potential.

The "Others" segment, which includes newer vaccine technologies like mRNA and viral vector vaccines, is the fastest-growing.

Will Comprehensive Ability to Provide Medical Care Fuel the Edible Vaccine Market?

The comprehensive ability of edible vaccines to enhance medical care can fuel market growth. Edible vaccines offer a promising, needle-free alternative to traditional vaccines, making immunization more accessible, especially in regions with limited healthcare infrastructure. This ability to simplify vaccine administration aligns with public health goals for increased vaccination coverage, particularly in areas where medical resources and trained personnel are scarce.

Additionally, edible vaccines reduce logistical challenges associated with cold-chain storage and distribution. As they can be produced and stored with minimal refrigeration needs, edible vaccines lower costs and improve reach in remote and underserved areas. This ease of distribution and storage supports broader healthcare initiatives, making edible vaccines an attractive option to expand medical care capabilities globally, further driving their market potential.

The Livestock segment is the fastest-growing, fueled by increasing demand for efficient, cost-effective solutions to manage animal diseases in agriculture.

Country/Region-wise

Will Advanced Healthcare Infrastructure in North America Drive the Expansion of The Edible Vaccine Market?

The advanced healthcare infrastructure in North America is likely to drive the expansion of the Edible Vaccine Market. With highly developed research facilities, the region is well-positioned to support innovation in vaccine delivery systems like edible vaccines, addressing the need for easier, needle-free alternatives. The United States, in particular, invests significantly in healthcare, with federal research funding for the National Institutes of Health (NIH) reaching approximately $47.5 billion in 2022, part of which supports vaccine research and development. This robust investment landscape accelerates breakthroughs in biotechnology, supporting edible vaccine advancements.

Furthermore, high vaccination rates and supportive regulatory frameworks in North America create a favorable environment for introducing novel vaccine types. For example, in 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported that approximately 72% of the population had received full COVID-19 vaccinations, showing widespread vaccine adoption and an openness to innovative health solutions. As demand for effective, accessible, and affordable vaccination options grows, edible vaccines are positioned to benefit from the region's sophisticated healthcare infrastructure and regulatory support, potentially leading to their expanded use in public health initiatives.

Will Rapid Economic Growth in Asia Pacific Propel the Edible Vaccine Market?

Rapid economic growth in the Asia-Pacific region is likely to propel the Edible Vaccine Market, primarily due to increased investment in healthcare infrastructure and a heightened focus on preventive health measures. As nations such as China and India continue to experience robust economic expansion, the demand for innovative healthcare solutions, including edible vaccines, is expected to rise significantly. According to the Asian Development Bank, the region's economy is projected to grow by approximately 5.5% in 2024, which will likely lead to increased government spending on health initiatives and improved access to vaccination programs.

Furthermore, the Asia-Pacific region faces a high burden of infectious diseases, which underscores the need for accessible vaccination solutions. The World Health Organization reported that vaccine-preventable diseases caused over 1.5 million deaths annually in low- and middle-income countries, many of which are located in this region. As governments aim to enhance immunization coverage, edible vaccines offer a viable alternative to traditional methods, facilitating easier distribution and administration. The combination of economic growth and an urgent health mandate creates a favorable environment for the Edible Vaccine Market to thrive in the Asia-Pacific region.

Competitive Landscape

The competitive landscape of the Edible Vaccine Market is characterized by rapid technological advancements and increasing innovation in diagnostic tools. Companies are focusing on developing more accurate, non-invasive, and user-friendly testing solutions to meet the growing demand for personalized and preventive healthcare. Strategic collaborations, mergers, and acquisitions are also common as firms aim to enhance their market presence and expand their product offerings.

Some of the prominent players operating in the Edible Vaccine Market include:

GlaxoSmithKline, Sanofi S.A., Merck & Co., Inc., Ceva, Santa Cruz Animal Health, Merial.

Latest Developments

In August 2024 A research team at the University of California developed an innovative oral vaccine using genetically modified edible plants. This new approach allows for easy administration without needles, potentially increasing vaccination rates. Early studies showed promising immune responses in animal models, indicating that this method could revolutionize how vaccines are delivered, particularly in underserved regions.

In July 2024 Syngenta announced a partnership with BioNTech to explore the development of edible vaccines using genetically engineered crops. This collaboration aims to leverage BioNTech's mRNA technology to create plants that can produce antigens for various diseases. The initiative could significantly reduce production costs and facilitate wider distribution of vaccines in developing countries.

In June 2024 the Food and Drug Administration (FDA) approved the first edible vaccine for rotavirus, developed by a biotechnology firm in collaboration with agricultural scientists. This landmark decision paves the way for future approvals of edible vaccines, highlighting a growing acceptance of plant-based vaccine technology. The vaccine is expected to be available in various food products, making it more accessible, especially for children in low-income countries.

Edible Vaccine Market, By Category

• Type:
• Inactivated Vaccines
• Others
• Application:
• Livestock
• Medical Care
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL EDIBLE VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL EDIBLE VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL EDIBLE VACCINE MARKET, BY APPLICATION

• 5.1 Overview
• 5.2 Livestock
• 5.3 Medical Care

6 GLOBAL EDIBLE VACCINE MARKET, BY TYPE

• 6.1 Overview
• 6.2 Inactivated Vaccines
• 6.3 Others

7 GLOBAL EDIBLE VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL EDIBLE VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 GlaxoSmithKline
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Sanofi S.A.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Merck & Co., Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Ceva
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Santa Cruz Animal Health
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Merial
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research